Hydrogenology
Hydrogenology editorial study record

Randomized, crossover clinical efficacy trial in humans and mice on tear secretion promotion and lacrimal gland protection by molecular hydrogen

Kubota M et al. · Sci Rep. 2021;11:6434.

HumanH₂-rich waterPublished 2021
Study record, not medical adviceThis page reports one source and Hydrogenology’s source-text extraction. It does not establish that molecular hydrogen is effective, safe or appropriate for any person. Human, animal and laboratory evidence must not be treated as equivalent.
Source and classification

What kind of evidence is this?

Evidence stream

Human

Reported design

Randomized two-period crossover exploratory human study with separate mouse experiments

Research topic

Eye health

Administration classification

H₂-rich water

Study result signal

Not reported in this record.

Outcome type

Not reported in this record.

Reported in the source

Methods at a glance

Population or model

Healthy adults, some reporting dry-eye symptoms

Sample

10 human participants

Duration

Acute measurements through 60 minutes after ingestion

Intervention

Ten persistent H₂-generating capsules consumed with 500 mL mineral water

Hydrogen form

Oral H₂-generating supplement — H₂ was generated after ingestion; not H₂-rich water and not Brown’s gas.

H₂ specification

The capsule-level H₂ dose was not quantified in the article.

H₂ flow

Not applicable — oral capsules, not gas inhalation.

O₂ delivered with H₂

No O₂ was co-delivered as part of the intervention.

Comparator

500 mL mineral water without the H₂-generating capsules; 1–3 day crossover interval

Reported, not endorsed

Outcomes and reported result

Outcomes measured

Exhaled H₂, tear stability, tear secretion and subjective ocular symptoms

Reported result

Exhaled H₂, tear stability and some dry-eye symptom measures improved after capsules. No side effects were reported; the human group was exploratory and very small.

Results-extraction completeness

Human intervention, methods, main results, funding and competing interests checked in the open-access full text; independent appraisal remains incomplete.

A reported association, difference or mechanism is not automatically a clinical benefit. Null findings, outcome type, study design and precision all matter.

Interpretation limits

Cautions and applicability

Design and reporting cautions

Only 10 healthy participants, acute crossover timing, multiple ocular measures and a separate mouse model. One sponsor-author was CEO of a dry-eye product company, helped design and write the study, and the company paid participant rewards.

Applies directly to

Healthy adults under the acute capsule protocol; not proof of treatment for diagnosed dry-eye disease.

Preliminary appraisal framework

Not reported in this record.

Preliminary risk-of-bias status

Not reported in this record.

Appraisal rationale

Not reported in this record.

No single-study GRADE certainty rating is assigned. Certainty is assessed by important outcome across a complete eligible evidence set, not by attaching a final grade to one source.

Provenance

Sources and record status

Identifiers

PMID: 33742060 · DOI: 10.1038/s41598-021-85895-y

Publisher access

Open-access full text is available through PMC and the publisher.

Extraction basis

Open-access PMC and publisher full texts plus PubMed bibliographic record.

Record revision

2026-08-10